A century-old pill costing just $4 a month slashes insulin needs by 12% in type 1 diabetes patients, defying medical expectations and challenging billion-dollar therapies.
Story Snapshot
- Garvan Institute RCT shows metformin reduces daily insulin by 12% in adults with type 1 diabetes over 6 months.
- No improvement in insulin resistance, yet stable blood sugar with less insulin burden.
- Off-label use already common in 10-13% of patients; first adult RCT confirms benefits.
- Researchers probe unknown mechanism after surprising results announced in November 2025.
- Promises easier management for millions, prioritizing cheap generics over costly innovations.
Garvan Institute Launches World’s First Adult RCT
Garvan Institute of Medical Research and UNSW Sydney conducted a 6-month randomized controlled trial with 40 adults. Participants received metformin or placebo alongside insulin therapy. Metformin cut daily insulin requirements by about 12% while maintaining stable blood sugar levels. This marked the first rigorous evidence for a practice already used off-label by up to 13% of type 1 patients in Australia.
Metformin Defies Expected Mechanism in Type 1 Diabetes
Researchers hypothesized metformin would improve insulin sensitivity in type 1 diabetes, mirroring its type 2 role. Trial results disproved this: no changes in insulin resistance occurred. Yet participants needed less exogenous insulin to control glucose. Dr. Snaith noted patients used 12% less insulin than placebo group. This unexpected outcome prompts deeper investigation into metformin’s action.
Metformin, derived from French lilac and available commercially for nearly 100 years, targets hepatic glucose production in type 2 diabetes. Type 1 diabetes destroys beta cells, mandating lifelong insulin since 1921. Off-label metformin use stemmed from anecdotal insulin resistance relief, affecting thousands before this RCT provided validation.
Lead Researchers Drive Evidence-Based Shift
Dr. Snaith, lead at Garvan, highlighted insulin burden reduction as a top priority for type 1 patients facing daily injections and hypoglycemia risks. Professor Jerry Greenfield, co-lead from Garvan and UNSW, stressed the mystery: metformin’s 100-year history leaves its exact mechanism unclear. Their academic partnership, free of pharmaceutical ties, focused on generic repurposing over expensive R&D.
Garvan and UNSW announced results in November 2025 via press releases. Off-label prescribing continues at 10-13% rates globally. No regulatory approvals for type 1 use followed yet, but mechanistic studies began post-trial to explain the insulin-sparing effect.
This cheap drug could help people with type 1 diabetes use less insulin https://t.co/KqoLpQ8u3t pharma education pic.twitter.com/irwPKE6PpV
— LifeScienceZone (@LifeScienceZon1) April 16, 2026
Transforming Daily Life and Care Economics
Type 1 diabetes burdens 8-10% of global diabetics with mental and physical insulin demands. A 12% reduction means fewer injections, lower hypoglycemia risk, and improved adherence. At $4 monthly, metformin democratizes relief, especially in resource-poor areas, contrasting high-cost insulins and biologics that strain budgets.
Short-term gains ease patient load; long-term shifts could update guidelines, favoring adjunctive generics. This challenges insulin-only paradigms, accelerating repurposed drug policies aligned with conservation of resources and patient empowerment over corporate profits.
Sources:
How a cheap, century-old drug can improve life with type 1 diabetes
Common drug found to reduce insulin needs in type 1 diabetes
Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes – PMC
